HER2+ Breast Cancer

Zahi Mitri, MD, discusses adjuvant advances and other emerging trends in the treatment of patients with HER2-positive breast cancer.

The combination of neratinib and T-DM1 induced an overall response rate of 60% in previously-treated women with HER2-positive metastatic breast cancer.

Rashmi K. Murthy, MD, discusses the clinical benefit of tucatinib after isolated brain progression in patients with HER2-positive breast cancer.

Long-term findings from a phase I study of trastuzumab deruxtecan showed that the investigational HER2-targeting antibody-drug conjugate had antitumor activity in multiple tumor types that expressed HER2 at varying levels.

Tucatinib used in combination with capecitabine, trastuzumab, or both agents showed promising antitumor activity in heavily pretreated women with HER2-positive breast cancer with or without brain metastases.

Evanthia Roussos Torres, MD, oncology fellow, Johns Hopkins University School of Medicine, discusses the importance of preclinical models in HER2-positive breast cancer.

Frances Valdes-Albini, MD, assistant professor of clinical medicine, Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses ongoing clinical trials of patients with HER2-positive breast cancer.

Adjuvant endocrine therapy alone is noninferior to adjuvant chemoendocrine therapy in patients with hormone receptor–positive, HER2-negative, node-negative early-stage breast cancer.